us irritable bowel syndrome treatment Market

The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 Mn in 2027 from US$ 586.61 Mn in 2019. The market is anticipated to grow with a CAGR of 10.3% from 2020-2027.

The growth of the US irritable bowel syndrome treatment market is primarily attributed to the increasing prevalence of irritable bowel syndrome and associated conditions, and increasing numbers of FDA approvals & drug developments. However, the limited number of product availability and treatment inefficiency is likely to restraint the growth of market during the forecast years.

Increasing number of FDA approvals and drug development activities are likely to accelerate the growth of the US irritable bowel syndrome treatment market during the forecast period. Majority of the established as well as new players are coming forward to manufacture drugs for the disease, which will lead to elevated availability of the drugs in the market. This availability of drugs is expected to boost the consumption, and hence the irritable bowel syndrome treatment market. For instance, in 2019, Ardelyx, Inc. got FDA approval for its Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The newly approved drug is a minimally-absorbed small molecule which acts locally in the gastrointestinal (GI) tract to decrease in abdominal pain and increase the bowel movements in IBS-C patients. Furthermore, in April 2019, SunGen Pharma Receives received FDA approval for its Dicyclomine Hydrochloride Injection USP, 20 mg/2 mL (10 mg/mL) to treat irritable bowel syndrome. The drug helps to reduce the symptoms of stomach and intestinal cramping.

The US irritable bowel syndrome treatment market is projected to witness introduction of generic drugs which will eventually have positive impact on the growth of the market. For instance, in 2020, Teva Pharmaceutical, and Israel based drug manufacturing company, recived FDA approval for its very first generic version irritable bowel syndrome drug Linzess (linaclotide). Additionally, according to company estimates, the drug is anticipated to observe thriving sales in the US market.

The US irritable bowel syndrome treatment market, based on the type was segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). In 2019, mixed IBS (IBS-M) segment held the largest share of the market. Also, IBS (IBS-M) segment is expected to grow at the fastest rate during the coming year.

The US irritable bowel syndrome treatment market, based on the product was segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, others. In 2019, linaclotide segment held the largest share of the market. Moreover, this segment is expected to grow at the fastest rate during the coming year

The US irritable bowel syndrome treatment market, based on the distribution channel was segmented into hospitals pharmacies, drug stores and retail pharmacies, and online pharmacies. In 2019, hospitals pharmacies segment held the largest share of the market. The drug stores and retail pharmacies segment is expected to grow at the fastest rate during the coming year easy accessibility to consumers.

Some of the major primary and secondary sources for immunochemistry included in the report are, World Health Organization, Food and Drug Administration and American Society for Gastrointestinal Endoscopy, Centers for Disease Control and Prevention (CDC), and International Foundation for Gastrointestinal Disorders, Inc. among others.